Dr Reddy’s Laboratories has signed an exclusive distribution agreement with Takeda Pharmaceutical Company to promote and distribute QDENGA, a dengue vaccine, in India’s private market.
The agreement covers vaccination for both children and adults. Subject to local regulatory processes, QDENGA is expected to become available in India in the first half of 2027.
The vaccine received marketing approval from the Central Drugs Standard Control Organisation (CDSCO) in July 2026 for people aged between 4 and 60 years, Dr Reddy’s said.
QDENGA is a live-attenuated tetravalent dengue vaccine designed to provide protection against all four dengue virus serotypes, DENV-1 to DENV-4. It is given in two doses, with the second dose administered three months after the first.
According to the companies, QDENGA is the first approved dengue vaccine in India.
Under the agreement, Dr Reddy’s will have exclusive responsibility for distributing QDENGA in the private market. It will also lead disease awareness activities and engage with healthcare professionals.
Takeda will continue to handle the public-market rights, legal ownership and overall medical and brand responsibilities for the vaccine.
M. V. Ramana, CEO of Global Generics at Dr Reddy’s Laboratories, said the launch of India’s first approved dengue vaccine would be an important development for the country’s healthcare sector.
He said the company expects its partnership with Takeda to help make QDENGA available to eligible people and support efforts to reduce the impact of dengue in India.
Dr Mahender Nayak, Head of Intercontinental Markets at Takeda’s International Business Unit, said the partnership would help provide private-market access to eligible individuals once the vaccine becomes available.
QDENGA has been approved in 43 countries and more than 32 million doses have been distributed globally, according to the companies.
The partnership comes as dengue continues to remain a major public health concern in India, with the two companies aiming to expand access to dengue vaccination through the private healthcare market.
